A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Inclusion Criteria: * Patients must have radiologically confirmed (ie, CAT scan and/or MRI) persistent or recurrent EC of epithelial origin that has progressed after prior platinum based chemotherapy or is refractory to platinum-based chemotherapy. * Must have availability of archival tumor tissue FFPE block for TROP-2 testing * Note: The presence or absence of TROP-2 overexpression will NOT determine eligibility for study enrollment. * The diagnosis must be histologically confirmed by a gynecologic pathologist. * All patients must have measurable disease. Measurable disease is defined as lesions which can be measured by physical examination or by means of medical imaging techniques. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpation or plain x-ray, or ≥ 10 mm when measured by spiral CT and/or MRI. Ascites and pleural effusions are not to be considered measurable disease. * Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST v1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence following completion of radiation therapy. * After undergoing surgery, patients may be optimally or sub optimally debulked. * Patien…